Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Author Correction: Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells.

Autor: van der Stegen SJC; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lindenbergh PL; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU Amsterdam, Amsterdam, the Netherlands., Petrovic RM; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Xie H; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Diop MP; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Alexeeva V; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shi Y; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Mansilla-Soto J; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Hamieh M; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Eyquem J; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Gladstone-UCSF Institute of Genomic Immunology, Gladstone Institutes, San Francisco, CA, USA., Cabriolu A; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Wang X; Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Abujarour R; Fate Therapeutics Inc, San Diego, CA, USA., Lee T; Fate Therapeutics Inc, San Diego, CA, USA., Clarke R; Fate Therapeutics Inc, San Diego, CA, USA., Valamehr B; Fate Therapeutics Inc, San Diego, CA, USA., Themeli M; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU Amsterdam, Amsterdam, the Netherlands., Riviere I; Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sadelain M; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA. m-sadelain@ski.mskcc.org.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. m-sadelain@ski.mskcc.org.

Publikováno v: Nature biomedical engineering [Nat Biomed Eng] 2024 Nov; Vol. 8 (11), pp. 1500.

CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.

Autor: Thayaparan T; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK., Petrovic RM; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK., Achkova DY; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK., Zabinski T; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK., Davies DM; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK., Klampatsa A; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK.; Pulmonary, Allergy & Critical Care Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Parente-Pereira AC; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK., Whilding LM; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK., van der Stegen SJ; The Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Woodman N; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK., Sheaff M; Department of Histopathology, Barts Health NHS Trust, The Royal London Hospital, London E1 2ES, UK., Cochran JR; Department of Bioengineering and Chemical Engineering, Stanford Cancer Institute, 443 Via Ortega, Room 356, Stanford, CA, USA., Spicer JF; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK.; Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Maher J; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK.; Department of Clinical Immunology and Allergy, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK.; Department of Immunology, Eastbourne Hospital, Kings Drive, Eastbourne, East Sussex, BN21 2UD, UK.

Publikováno v: Oncoimmunology [Oncoimmunology] 2017 Aug 14; Vol. 6 (12), pp. e1363137. Date of Electronic Publication: 2017 Aug 14 (Print Publication: 2017).

Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?

Autor: van der Stegen SJ; Department of Research Oncology, King's Health Partners Integrated Cancer Centre, King's College London, London SE1 9RT, United Kingdom;, Davies DM, Wilkie S, Foster J, Sosabowski JK, Burnet J, Whilding LM, Petrovic RM, Ghaem-Maghami S, Mather S, Jeannon JP, Parente-Pereira AC, Maher J

Publikováno v: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2013 Nov 01; Vol. 191 (9), pp. 4589-98. Date of Electronic Publication: 2013 Sep 23.

Opioidergic mechanisms are not involved in the antihyperalgesic effects of carbamazepine and oxcarbazepine.

Autor: Stepanovic-Petrovic RM; Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia. racabbr@eunet.yu, Tomic MA, Vuckovic SM, Ugresic ND, Prostran MS, Boskovic B

Publikováno v: Methods and findings in experimental and clinical pharmacology [Methods Find Exp Clin Pharmacol] 2007 Apr; Vol. 29 (3), pp. 191-4.